Inflammatory Diseases Research
Research in the Centre for Inflammatory Diseases (CID) spans basic experimental biology, clinical research and clinical practice in inflammatory diseases.
Research groups
Atherosclerosis and Cardiovascular Inflammation Group
Heart disease is the number one killer in our community. The underlying basis of it is the thickening of arteries by the pathological process of atherosclerosis; an occlusive disease of arteries that causes heart attacks and strokes.
Autoimmune Kidney Disease and Vasculitis Research Group
White blood cells are central to the development of severe forms of human glomeraula inflammation. They are also increasingly recognised as important in acute kidney (renal) injury, a common complication of hospital stays that increases the chance of a poor clinical outcome.
Cancer Immunology Group
The Cancer Immunology Group focuses on identifying immunogenic HLA-presented tumour neoantigens for precision T-cell receptor therapy for cancer.
Cell Based and Regenerative Therapies for Inflammatory Bowel Disease
Our aim is to discover novel regenerative and cell based therapies that will reverse the gut inflammation driving this disease.
Chronic Kidney Disease and Transplantation Research Group
Type 2 diabetes is a metabolic syndrome is caused by the development of insulin resistance, which is normally a consequence of chronic obesity.
Inflammatory Respiratory Disease Research Group
Chronic Obstructive Lung Disease (COPD) is the fourth major killer worldwide. Smoking and pollution are major factors.
Leukocyte Trafficking Group
Leukocytes play critical roles in protective responses to infection and injury. However, these same cells are also major contributors to inappropriate, injurious responses in inflammatory diseases.
Liver/Gut Inflammation and Fibrosis Research Group
Liver fibrosis and cirrhosis is the common end stage to all liver diseases in humans. We study mechanisms of liver fibrosis and factors that determine its progression to cirrhosis.
MOnash digital Therapeutics and Innovation Laboratory (MoTILa)
MOnash digital Therapeutics and Innovation Laboratory (MoTILa) is led by Associate Professor Suong le.
Monash Infectious Diseases
The Infectious Diseases Research Group conducts a wide range of basic, clinical and translational research and quality assurance activities.
Monash Sjögren Registry
The Monash Sjögren Registry is an initiative dedicated to improving the understanding, diagnosis, and management of Sjögren disease—a chronic autoimmune condition that is often under-recognised and misdiagnosed. This registry aims to collect quality data to support long-term research into Sjogren disease, in order to enhance patient care, and drive the development of more effective treatments.
Regulatory T Cell Therapies Research Group
The Regulatory T Cell Therapies lab focusses on generating autoantigen-specific regulatory T cells to treat autoimmune diseases.
Rheumatology Group
The Rheumatology Group includes senior clinicians and laboratory researchers with backgrounds in rheumatology, kidney disease, immunology, clinical trials, lupus and arthritis.
Stroke and Imaging Inflammation Group
Inflammation is one of the first responses of the immune system to infection or injury. Our laboratory uses cutting edge in vivo imaging techniques to directly visualise and study the immune processes involved in inflammation in both infectious and non-infectious models.
Targeted Nanomedicines Group
Targeted Nanomedicines Group focuses on developing organ-specific immunomodulatory nanoparticles to treat inflammatory diseases.
Translational Kidney Therapies Group
The Translational Kidney Therapies Group is working on new innovative therapies to target inflammatory kidney diseases such as: ANCA associated vasculitis, glomerulonephritis, and acute kidney injury, with a particular focus on modulating the immune system with therapies that reduce inflammation and target the particular immune cells that cause the pathological damage.